PDGFRA and gastrointestinal stromal tumor: The observation of lower [18F]FDG uptake in the PDGFRA D842V-mutant GISTs subgroup compared to with other GIST subgroups is particularly relevant for treatment response evaluation, given the recent advent of avapritinib as a new standard of care for this subset of GISTs, and might allow reduction of costs and radiation exposure.